Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLINASDAQ:BTAINASDAQ:NTBLNASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.18+4.0%$1.09$0.72▼$8.09$9.33M0.35359,275 shs194,502 shsBTAIBioXcel Therapeutics$1.69+10.5%$1.61$1.17▼$25.92$10.27M0.081.20 million shs99,814 shsNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shsSLXNSilexion Therapeutics$0.94+1.6%$0.91$0.58▼$41.85$8.14M0.125.06 million shs145,584 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+0.89%+0.89%-6.61%-31.52%-82.74%BTAIBioXcel Therapeutics0.00%+24.39%-3.16%-54.60%-94.13%NTBLNotable Labs0.00%0.00%0.00%0.00%-73.91%SLXNSilexion Therapeutics-2.99%-4.01%-5.69%-30.71%+92,149,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics4.3959 of 5 stars3.55.00.04.72.60.80.6BTAIBioXcel Therapeutics3.9425 of 5 stars3.33.00.04.51.51.70.6NTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,453.19% UpsideBTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,420.71% UpsideNTBLNotable Labs 2.00HoldN/AN/ASLXNSilexion Therapeutics 3.00Buy$5.00434.19% UpsideCurrent Analyst Ratings BreakdownLatest NTBL, SLXN, BCLI, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025SLXNSilexion TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $5.003/19/2025BTAIBioXcel TherapeuticsRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025BTAIBioXcel TherapeuticsRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ABTAIBioXcel Therapeutics$1.85M5.53N/AN/A($30.21) per share-0.06NTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04SLXNSilexion TherapeuticsN/AN/A$0.64 per share1.46($6.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)BTAIBioXcel Therapeutics-$179.05M-$13.55N/AN/AN/A-3,119.33%N/A-105.04%8/5/2025 (Estimated)NTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/ASLXNSilexion Therapeutics$260KN/A0.00∞N/AN/AN/A-249.43%6/17/2025 (Estimated)Latest NTBL, SLXN, BCLI, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/13/2025N/ASLXNSilexion TherapeuticsN/A-$0.26N/A-$0.26N/AN/A5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million3/27/2025Q4 2024BTAIBioXcel Therapeutics-$4.36-$3.57+$0.79-$3.57$0.72 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.050.05BTAIBioXcel TherapeuticsN/A1.871.81NTBLNotable Labs0.032.772.77SLXNSilexion TherapeuticsN/A0.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%BTAIBioXcel Therapeutics30.68%NTBLNotable Labs70.48%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%BTAIBioXcel Therapeutics21.20%NTBLNotable Labs1.20%SLXNSilexion Therapeutics33.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableBTAIBioXcel Therapeutics906.06 million2.44 millionOptionableNTBLNotable Labs409.02 million9.54 millionNo DataSLXNSilexion TherapeuticsN/A8.69 million1.07 millionN/ANTBL, SLXN, BCLI, and BTAI HeadlinesRecent News About These CompaniesSilexion Therapeutics announces preclinical results on SIL204May 30, 2025 | finance.yahoo.comSilexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal TumorsMay 30, 2025 | msn.comSilexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung CancersMay 29, 2025 | finance.yahoo.comSilexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant CancersMay 23, 2025 | nasdaq.comSilexion Therapeutics Receives Nasdaq Delisting NoticeMay 23, 2025 | tipranks.comPESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer TreatmentMay 22, 2025 | globenewswire.comSilexion Therapeutics Corporation Registered ShsMay 22, 2025 | markets.businessinsider.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung CancerMay 21, 2025 | finance.yahoo.comSilexion Therapeutics Completes Preclinical Study on SIL204 for Expanded KRAS-Driven Cancer TherapiesMay 21, 2025 | quiverquant.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung CancerMay 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | finanznachrichten.deSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSilexion Therapeutics enters collaboration with CatalentApril 25, 2025 | markets.businessinsider.comSilexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven CancersApril 23, 2025 | quiverquant.comSilexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing ActivitiesApril 23, 2025 | globenewswire.comSilexion Therapeutics announces expanded development plan for SIL204March 28, 2025 | markets.businessinsider.comSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28, 2025 | globenewswire.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 ConferenceMarch 21, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTBL, SLXN, BCLI, and BTAI Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.18 +0.05 (+3.98%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.BioXcel Therapeutics NASDAQ:BTAI$1.69 +0.16 (+10.46%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Notable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.Silexion Therapeutics NASDAQ:SLXN$0.94 +0.01 (+1.57%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Market’s Silent Warning: What Bonds and Gold Reveal AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
